Nonalcoholic fatty liver disease (NAFLD) is probably the most common liver disorder in the world.\(^1\) Globally, NAFLD is pandemic with an estimated prevalence of 20%–30% in Western countries and 5%–18% in Asia, which is expected to increase over time. The prevalence is rising in recent years due to changes in dietary habits being more westernized and owing to increase of sedentary lifestyle thus placing a worry on NAFLD becoming the main cause of liver disease among young adults and children.\(^1\)

There is a considerable need to treat NAFLD patients because they have a 1.7-fold increase in standardized age and gender-matched mortality.\(^1\) The most common cause of death in patients with NAFLD and nonalcoholic steatohepatitis (NASH) is cardiovascular events, but they also have an increased liver-related mortality rate particularly when advanced fibrosis, cirrhosis, and hepatocellular carcinoma (HCC) develop.\(^2,3\) Currently, there is no medicine that can be considered as the standard of care for the treatment of NASH.\(^4,5\) All available medications that are recommended for the treatment of NAFLD with or without scientific rationale and includes agents for weight loss, insulin sensitizers, drugs that reduce blood lipids, glucagon-mimetics, drugs that may reduce fibrosis, angiotensin receptor blockers, and medicines believed to reduce endoplasmic reticular stress such as vitamin E, ursodeoxycholic acid, and S-adenosyl methionine. A quick review of the newer agents that proved to be promising such as obeticholic acid and GFT505 and the medicines that are still in the pipeline is also presented.

Key Words: Insulin sensitizers, liver protectors, Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis, Ursodeoxycholic acid, vitamin E

Received: 16.07.2015, Accepted: 23.01.2016
How to cite this article: Dajani A, AbuHammour A. Treatment of nonalcoholic fatty liver disease: Where do we stand? an overview. Saudi J Gastroenerol 2016;22:91-105.
LIFESTYLE MODIFICATIONS AND WEIGHT LOSS

Life style modifications include attention to patient’s physical activity and in addition to that of encouraging weight loss, which could be achieved by dietary control in conjunction, in some instances, of medicines that help losing weight such as orlistat, or of bariatric surgery. Lifestyle modification should be stressed as being central to all therapeutic modalities despite the difficulties in implementing it by the patients.

Weight loss

In a recent meta-analysis of randomized trials, it was observed that weight loss of at least 7% is effective in improving histological disease activity, although it was achieved by less than 50% of patients. A greater weight loss (up to 10%) may be needed to improve necro-inflammation as well. The optimal dietary composition for NAFLD patients is variable as per different authors but physicians should plan a clear target that genuinely leads to loss of weight through carbohydrate and lipid restriction. The Mediterranean dietary pattern has gained interest as it showed that it might have a beneficial effect on both prevention and resolution of the metabolic syndrome. It is known that physical activity reduces the risk of impaired fasting glucose, type 2 diabetes mellitus (T2DM), insulin resistance (IR), hypertension, dyslipidemia, and the metabolic syndrome, which are main conditions that co-exist with NAFLD and contribute to its pathogenesis. Two analyses carried out in the cohort of the Look AHEAD Study—a multicenter prospective study that compared intensive lifestyle intervention, including caloric restriction and at least 175 min of moderate aerobic physical activity per week, to standard care in diabetic subjects-reported that after 1 year of intervention there was a significant decrease in hepatic fat content and a reduced incidence of NAFLD in patients randomized to the intensive lifestyle group. Improving physical activity is the most powerful determinant of lifestyle intervention to correct metabolic indices, and the elevated liver enzymes due to NAFLD. Patients who could perform a 150- to 300-min exercise per week for 16 weeks had a significant improvement in their hepatic steatosis. In this respect both aerobic and endurance exercises were found to have a positive impact on steatosis even if the patient could not lose weight.

Orlistat

The results from studies evaluating treatment with orlistat were inconsistent. An earlier randomized controlled study showed that orlistat improved alanine transaminase (ALT) and steatosis for NAFLD patients. Whereas a subsequent randomized controlled trial (RCT) showed that orlistat in combination with caloric restriction and vitamin E (800 IU/day) did not enhance weight loss, improve liver enzymes, or improve histopathology compared with caloric restriction and vitamin E only. In that study, the authors found that ≥ 9% weight loss resulted in improved histology irrespective of whether patients received orlistat or placebo.
Of note, when treatment with orlistat is initiated, it should be discontinued after 12 weeks if patients have been unable to lose at least 5% of the body weight as measured at the start of therapy. Furthermore, treatment duration should not be greater than 1 year as there is potential for fat-soluble vitamin deficiency if continued for longer.\(^{[19]}\)

**Bariatric surgery (gastric bypass)**

NAFLD *per se* is not an indication for bariatric surgery.\(^{[15]}\) However, bariatric surgery-induced weight loss appears to have beneficial effects on lipid profile, hepatic steatosis, steatohepatitis, as well as reducing long-term mortality.\(^{[16,17]}\) The type of surgery seems to be relevant to the effect on NAFLD; gastric bypass produces the largest sustained weight loss compared with other bariatric procedures.\(^{[15]}\) Because long-term outcome data about bariatric surgery as a specific treatment for NAFLD is lacking, bariatric surgery cannot be considered as a primary treatment for NASH. Surgery should be considered, however, as a first-line option for the treatment of obesity in adults with a body mass index (BMI) greater than 50 kg/m\(^2\). It is also important to note that bariatric surgery should be avoided in subjects with advanced cirrhosis and portal hypertension because rapid weight loss in these patients may increase the risk of hepatic decompensation.\(^{[18]}\) More RCTs may be needed to validate the fact that bariatric surgery could be contemplated as a first-line treatment for NASH.\(^{[16,19]}\)

**Therapeutic medicines**

The medicines that are being used in the management of NAFLD in every day practice include the standard medications that are usually used to treat the associated conditions. Table 1 summarizes the common medicines used in this respect and their role in treating NAFLD. However, evaluation of investigational trends targeting pathological concepts of the disease itself is being considered and so is the situation with newer medicines in development in the pipeline. Table 2 displays the most important medicines being investigated or studied for future production. Traditionally some conventional medicines and phytomedications have been used in certain cultures, together with hepatoprotective agents in the management of NAFLD; these drugs are briefly discussed in the following sections.

**Insulin sensitizers**

These include medicines that affect hepatic liver partitioning by decreasing insulin resistance, modifying adipocyte differentiation, inhibiting vascular endothelial growth factor (VEGF)-induced angiogenesis, decreasing leptin and increasing adiponectin levels, and decreasing levels of certain interleukins (eg, IL-6).\(^{[66]}\) Metformin, rosiglitazone, and pioglitazone had been used in this respect alone or in different combinations with other medicines.\(^{[67]}\)

Clinical experience revealed variable results with metformin with temporary improvement of transaminases but most studies that were done did not have a histologic proof.\(^{[20]}\)

Only pioglitazone was believed to induce a convincing effect, however, it should be noted that relapse was common when these medicines were stopped and hence it should be used for a very long period of time, which raises worries with pioglitazone about the risk of cardiovascular events,\(^{[66]}\) increase in body weight,\(^{[68]}\) increase in fracture risk,\(^{[66,68,69]}\) and increase in the incidence of bladder and prostatic cancer.\(^{[66]}\) Pioglitazone also appeared to work best and have a better prognosis in the nondiabetic patient where its effects seem to be least relevant to clinical outcome (steatosis, ballooning).\(^{[25]}\)

**Drugs that reduce blood lipids**

Fibrates, peroxisome proliferator-activated receptor (PPAR)-\(\alpha\) agonists, were found to have anti-inflammatory and antifibrotic effects on the liver of experimental animals. In particular they were successful in preventing tamoxifen-induced steatosis in rats. In humans, however, this was not confirmed. A pilot study revealed that gemfibrozil had resulted in biochemical improvement of transaminases, but histologic data were lacking.\(^{[70]}\)

Statins appeared to have some good effect in NAFLD in many open-label studies\(^{[71]}\) particularly atorvastatin,\(^{[29]}\) which has been extensively studied in the literature. Given the lack of evidence to show that patients with NAFLD and NASH are at increased risk for serious drug-induced liver injury from statins, statins can be used to treat dyslipidemia in patients with NAFLD and NASH.\(^{[71]}\) However, until more RCTs with histological endpoints prove their efficacy, statins should not be used to specifically treat NASH alone.\(^{[71]}\)

Rosuvastatin used for NAFLD had also improved glucose intolerance, insulin sensitivity, and liver histology\(^{[27,31]}\) in a dose-dependent manner. Animal experiments in obese mouse model indicated that it would change the fat distribution from visceral to subcutaneous fat depot.\(^{[72]}\) Consequently, rosuvastatin therapy may be of great help to patients with metabolic syndrome because it has a wide range of beneficial pleiotropic effects.\(^{[72,73]}\) In a case study when rosuvastatin was combined with pioglitazone they led to rapid and sustained improvement of biochemical and ultrasonographic markers of resistant, severe NAFLD.\(^{[74]}\)

Ezetimibe which blocks Niemann-Pick C1-Like 1 (NPC1L1) pathway of hepatic cholesterol uptake\(^{[75,76]}\) to lower hepatic free and total cholesterol stores emerged as a promising
Animal studies in high fat/high cholesterol-fed mice and FOZ/FOZ mice had documented its antisteatotic, anti-apoptotic, anti-inflammatory, and antifibrotic therapeutic effects. Ezetimibe has been tested alone, and in combination with weight loss and/or orlistat. More studies are needed in humans to confirm this concept.

| Intervention | Main author | Selected studies | Transaminases | Fibrosis | Conclusion of all included studies |
|--------------|-------------|------------------|---------------|----------|-----------------------------------|
| **Medicines that are used for treatment of associated comorbid disease and may benefit NAFLD at the same time** | | | | | |
| Metformin | Insulin sensitizer | Marchesini[20] | Pilot | Improved | NA | Improved |
| | | Bugianesi[21] | RCT | Improved | positive response | No change |
| | | Uygun[22] | RCT | Improved | No change | No change |
| | | Lavine[23] | RCT | Improved | No change | No change |
| | | Maaza[24] | RCT | No effect | No change | No change |
| Pioglitazone | Insulin sensitizer | Shadid[25] | OL | Improved | NA | NA |
| | | Aithal[26] | OL | Improved | Positive response | No change |
| | | Sanyal[27] | RCT | Improved | Positive response | Positive response |
| | | Mahady[28] | Meta-analysis | Improved | Positive response | Positive response |
| Atorvastatin | Lipid partitioning | Foster[29] | RCT | Improved | Positive response | Positive response |
| | | Gomez[30] | OL | Improved | NA | NA |
| | | Horlander[31] | OL | Improved | NA | NA |
| | | Kiyci[32] | OL | Improved | NA | NA |
| Ezetimibe | Lipid partitioning | Park[33] | OL | Improved | Positive response | Positive response |
| | | Loombar[34] | RDBCT | Improved | Positive response | Positive response |
| Vitamin E | Anti-oxidant | Lavine[35] | OL | Improved | NA | NA |
| | | Hasegawa[36] | Pilot | Improved | NA | NA |
| | | Harrison[37] | RCT | Improved | Improved FS | Improved FS |
| Sylimarine | Antioxidant | Cacciapuoti[38] | OL | Improved | NA | NA |
| | | Solhi[39] | RCT | Improved | NA | NA |
| | | Hashemi[40] | PCT | Improved | NA | NA |
| Pentoxifylline | Anti-fibrotic | Wenjun[41] | Review | Improved | Positive response | Positive response |
| | | Zein[42] | RCT | Improved | Positive response | Positive response |
| ARBs | Anti-hypertensives with probable antifibrotic effect | Georgescu[43] | RCT | Improved | Positive response | Positive response |
| | | Abu Dayyeh[44] | OL | NA | No effect | No effect |
| | | Lugo-baruqui[45] | OL | Improved | NA | NA |
| | | Yokohama[46] | Pilot | Improved | Positive response | Positive response |
| EPL | Hepatoprotector | Gonciarz[47] | RCT | Improved | Mild response | NA |
| | | Arvind[48] | RCT | Improved | NA | Positive response |
| | | Dajani[49] | OL | Improved | Positive response | Positive response |

Ezetimibe has been tested alone, and in combination with weight loss and/or orlistat. More studies are needed in humans to confirm this concept.
### Table 2: Investigational medicines and specific medicines targeting NAFLD or its pathologic components being produced in the pipeline

| Medicine                  | Category                                  | Reference                      | Status                  | Comment                                                                 |
|---------------------------|-------------------------------------------|---------------------------------|-------------------------|-------------------------------------------------------------------------|
| EPA-E                     | Poly-unsaturated fatty acid               |                                |                         | Results controversial. EPA treatment seemed to be safe and efficacious for patients with NASH, in some studies, with others showed no significant effect on the histologic features of NASH. |
| Multistrain biotic L. rhamnosus L. bulgaricus | Probiotic                                | Yan-yan Ma[53]                  | Meta-analysis OL RCT    | Probiotic therapies can reduce liver aminotransferases, total-cholesterol, TNFα and improve insulin resistance in NAFLD patients. Modulation of the gut microbiota represents a new treatment for NAFLD                                                                   |
| Simtuzumab                | Anti-lysyl oxidase MAB (GS-6624)          | Naoki[54]                       | RCT phase II            | Antibody-mediated LOXL2 inhibition effectively suppressed collagen cross-linking during experimental liver fibrosis progression in vivo                                                    |
| Obeticholic acid          | Farnesoid X receptor (FXR) agonist        | Mudaliar[55]                    | DBRCT                   | In phase 2 trial, OCA was well tolerated, increased insulin sensitivity, and reduced markers of liver inflammation and fibrosis in patients with type 2 diabetes mellitus and NAFLD                                                                       |
| GFT505                   | PPAR α/δ agonist                          | Cariou[56]                      | DBRCT                   | Pre-clinical and clinical data had revealed improvement of insulin resistance, decrease in triglycerides and LDL levels and significant improvement of the liver transaminases                                                      |
| DUR-928                  | Regulatory new chemical entity for lipid homoeostasis | Dursct[57]                     | Animal experiment       | http://www.durect.com/wt/durect/page_name/DUR-928. Accessed on May, 25th 2015                                   |
| GR-MD-02                 | Galactin inhibitor                        | Traber[61]                      | Animal experiment preclinical | Phase I clinical study evaluated the safety, tolerability, and drug pharmacokinetics for single and multiple doses of GR-MD-02 when administered to human patients of NASH with advanced fibrosis                                                  |
| Aramchol                  | Arachidic and Cholic acid                 | Safadi[62]                      | RCT                     | Aramchol is safe, tolerable, and significantly reduces liver fat content in patients with NAFLD                                                                          |
| RG-125 (AZD4076) Cenicriviroc CVC | Insulin sensitizer CCR2 and CCR5 pathway inhibitor | Regulus report[64]            | Preclinical RCT         | Dual inhibitor of the chemokine receptors CCR2 and CCR5 pathways which is important for inflammation and fibrosis. Indicated for the treatment of nonalcoholic steatohepatitis, or NASH, in patients with liver fibrosis |

### MEDICINES THAT TARGET ANTIOXIDANT ACTIVITY AND REDUCE ENDOPLASMIC RETICULAR STRESS

Vitamin E was studied extensively alone and in combination with pioglitazone, vitamin C, “essential” phospholipids (EPL), sylmarin, and metformin with variable results and a general consensus that its effects are very limited and dubious. Vitamin E is currently the most widely assessed antioxidant; several questions yet need to be answered, including the proper dosage needed to induce a beneficial histologic change, long-term tolerance, and efficacy of vitamin E in particular subsets, such as diabetes and NASH-related cirrhosis. Based on the available evidence, vitamin E (RRR-α-tocopherol) is currently only recommended in NASH adults without diabetes or cirrhosis and with aggressive histology. Validation is needed in children before its use can be recommended, although a recent study indicated that Vitamin E has been shown to be effective and safe in improving NASH histology in children. A meta-analysis warned that the high doses of vitamin E that are usually effective to treat NASH should be used with extreme caution as they had increased all-cause mortality from any disease, prostatic cancer, and hemorrhagic strokes. Longer follow-up of RCTs are needed to assess long-term vitamin E safety.

### Ursodeoxycholic acid

Ursodeoxycholic acid (UDCA) was theoretically believed to improve patients with steatosis, however, results of treatment with UDCA were variable and nonconclusive. Recent multicenter clinical studies of large scale populations with UDCA in NAFLD and NASH revealed inconsistent and disappointing results; hence UDCA was not recommended by the AASLD, EASL, and ACG for the treatment of NAFLD or NASH as per their treatment guidelines. Furthermore, UDCA is known to inhibit DNA repair, co-enzyme A, cyclic AMP, P53, phagocytosis,
and induction of nitric oxide synthetase. This renders it with a possible genotoxic effect. UDCA toxicity is related to its interference with drug detoxification, being hydrophilic and antiapoptotic, which leads to a remarkable list of unanticipated toxicity events.

**Glucagon mimetics**

The Glucagon mimetics, including the dipeptidyl peptidase-4 (DPP-4) inhibitors (sitagliptin, vildagliptin, saxagliptin, linagliptin, and alogliptin), and the GLP-1 agonists (Exanitide, Liraglutide, and Exenidin-4) appeared to reduce hepatocyte steatosis and improve survival of the hepatocyte by enhancing the unfolded protein response (UPR) and promoting macroautophagy. The serum DPP-4 activity invariably increases in cirrhosis and several liver diseases. This increase is correlated with the prognosis of liver disease. DPP-4 activity was higher in NASH patients who compared with controls and the activity correlated with BMI. These changes in NASH might result either primarily from the underlying liver disease or secondary to insulin resistance.

A study on NASH aimed at developing markers such as DPP-4 that would enable detecting patients with high risk of progressive fibrosis and to develop effective treatment for the disease suggested that DPP-4 inhibitors could be potential candidate for NASH treatment. Incretin-based therapies, including DPP-4 inhibitors and GLP-1 analogues have appreciable experimental and clinical data available in this respect so far.

GLP-1 analogues are known to improve insulin resistance and are even more attractive because they have anorexigenic potential leading to weight loss, serum glucose and lipids improvement. Those, as well as DPP-4 inhibitors, might also be involved in direct pathways of liver fat elimination. A growing body of literature suggests that GLP-1 and DPP-4 activity have numerous effects on the cells of various organs. The data regarding GLP-1 analogues and DPP-4 inhibitors action on hepatocytes are convincing, but so far only T2DM patients with NAFLD/NASH have been studied with incretin analogues or DPP-4 inhibitors. Further studies are needed in order to assess the long-term effect of incretin-based therapies on NAFLD.

**MEDICINES TARGETING NALFD-INDUCED FIBROSIS**

Pentoxifylline, the phosphodiesterase inhibitor (PDE I), had been investigated in the management of NAFLD-induced fibrosis. A few RCTs, several open-label studies, and a meta-analysis have shown that it may have an antioxidant and antifibrotic effect. Pooled results showed that pentoxifylline significantly reduced the serum transaminase activity in NAFLD patients compared with placebo. It also significantly improved steatosis, lobular inflammation, and fibrosis and led to significant reduction in BMI, and fasting glucose, but did not significantly affect the serum tumor necrosis factor-α (TNFα) and adiponectin levels when compared with placebo. It is therefore a potential agent that may be useful to induce regression or at least halt fibrosis progression. It is generally safe and effective. Patients with T2DM and advanced proliferative retinopathy or tendency to retinal bleeding should use this medicine under strict observation and close follow up.

**POSSIBLE ROLE FOR THE RENIN–ANGIOTENSIN SYSTEM**

Angiotensin Receptor Blockers (ARBs) are also in the focus of investigation as a possible treatment for NAFLD. It is believed that ARBs by targeting the pancreatic effects of angiotensin should be able to preserve an adequate insulin secretion and acquire a better metabolic balance. Several clinical and research studies documented these effects and had shown that ARBs improve the intracellular insulin signaling pathway, provide better control of adipose tissue proliferation and adipokine production, produce more balanced local and systemic levels of various cytokines, prevent fibrosis, and slow down the vicious cycle that links steatosis to necroinflammation. There are a few RCTs on the effects of ACE-I or ARB in patients with NAFLD and most data are from retrospective studies, pilot prospective studies and post hoc analyses of clinical trials. Accordingly, more and larger RCTs are needed to directly assess the effectiveness of ACE-I and ARBs in NAFLD.

**S-adenosyl methionine**

S-adenosyl methionine (SAMe) is a medication that has been used for some chronic liver disorders. SAMe is a nutritional supplement that theoretically exerts its effect by donating a (CH3) group to an acceptor substrate in the trans-methylation process, and other metabolic reactions involving substrates, such as nucleic acids, proteins, lipids, and secondary metabolites. It was initially recommended for the treatment of depression, osteoarthritis, noncalculous chronic cholecystitis, cholangitis, intrahepatic cholestasis, and liver damage caused by drugs (antibiotics, antiviral preparation, and tricyclic antidepressants). There are a few uncontrolled pilot studies in the literature about its therapeutic applications in humans with no strong evidence base yet furnished; most of the data we know are based mainly on animal studies.

A clinical study evaluating its potential use in NAFLD is being investigated and is in phase III. It is noteworthy that, this medicine should be used with extreme caution in patients with bipolar disorders where depression could
be converted to mania, in patients with Parkinson’s disease which could worsen with the use of SAMe and in patients planned for or undergoing any surgery because of its effects on the central nervous system.

**Polyunsaturated fats 3n PUF (ethyl-eicosapentaenoic Acid EPA-E)**
Animal experiments demonstrated that EPA-E attenuates progression of hepatic fibrosis that has already developed in steatohepatitis.\(^{[50]}\) Moreover, the antifibrotic effect of EPA-E may be mediated by direct inhibition of reactive oxygen species (ROS) production, which involves a TGF-β-stimulated signaling pathway and/or fatty acid oxidation. These mechanisms, independent of the effect against triglyceride accumulation, may contribute to the therapeutic efficacy of EPA-E in NASH patients. A few clinical pilot studies indicated that it may exert a positive effect on reducing hepatic triglycerides and improving NAFLD.\(^{[50]}\)

In one of these studies using highly purified EPA-E the serum alanine aminotransferase levels were significantly improved, and serum free fatty acids, plasma soluble TNF receptor 1 and 2 levels, and serum ferritin and thioredoxin levels, which may reflect hepatic oxidative stress, were significantly decreased. Body weight, blood glucose, insulin, and adiponectin concentrations remained unchanged. Hepatic steatosis and fibrosis, improved in seven out of the 23 patients endorsing post-treatment biopsy.\(^{[51]}\) More research is ongoing to evaluate this concept and to furnish convincing evidence that it really might work; however, in a recent large scale phase II trial, EPA-E reduced subjects’ levels of triglyceride as compared with placebo but had revealed no significant effect on the histologic features of NASH.\(^{[52]}\)

**Probiotics**
It is well known that dysbiosis may lead to insulin resistance, and obesity by virtue of bacterial translocation. Both are important components of the metabolic syndrome and NAFLD.\(^{[92]}\) Bacterial translocation leads to mitochondrial dysfunction by causing an increased production of ROS in the Kupffer cells and hepatocytes, by upregulating nitric oxide synthetase (NOS) through the activation of both endothelial and inducible NOS.\(^{[51]}\) Furthermore LPS compounds that arise from bacterial translocation will also activate the Kupffer cells and induce them to produce pro-inflammatory cytokines besides the ROS.\(^{[53,55,92,94]}\) The net result will be fat accumulation in the liver.\(^{[51]}\) Clinical research had shown that bacterial translocation from the gut to the liver has an important role in the pathogenesis of NAFLD with its entire spectrum.\(^{[51]}\) Re-instating the microbiota of the gut therefore appears an interesting target to ameliorate dysbiosis and probably treat NAFLD.\(^{[51,93,94]}\) The preliminary results of research testing different probiotic preparations in this respect had yielded encouraging results and indicated that it could be an emerging therapeutic tool of potential great benefits.\(^{[95]}\) It remains to decide how and when to use this modality of treatment.

**Obeticholic acid**
Obeticholic acids (OCAs) are modified bile acid that change the body metabolism of lipids and might be beneficial for NASH.\(^{[57]}\) It was found to improve insulin sensitivity,\(^{[57,96]}\) and reduce serum triglyceride levels.\(^{[57]}\) OCAs were initially recommended as a monotherapy for primary biliary cirrhosis and were being investigated in NAFLD.\(^{[57]}\) NASH-FLINT study is a multicenter, randomized, double-blind, placebo-controlled, phase IIb clinical trial of treatment with either OCA or placebo in patients with NASH.\(^{[96]}\) The trial aimed to determine if administration of the farnesoid X receptor (FXR) ligand OCA for 72 weeks to subjects with biopsy evidence of NASH will result in improvement in their liver disease as measured by changes in the NAFLD activity score (NAS). An interim analysis, however, found that OCA showed improved efficacy on NASH-related liver health (P = 0.0024) and supported a decision to not perform end-of-treatment biopsies in 64 of the patients. Forty-five percent of the patients in the OCA group who were meant to have biopsies showed improved liver histology versus 21% of the patients in the placebo group (RR 1.9, 95% CI 1.3-2.8; P = 0.0002).\(^{[96]}\) Results also showed increases in total low-density lipoprotein (LDL) cholesterol and decreases in high-density lipoprotein (HDL) cholesterol in the OCA treatment group; it was then decided to discontinue treatment but continue the study. No continued cholesterol increases were seen after discontinuing OCA. Furthermore, improvements in liver enzymes with OCA were not sustained after discontinuing treatment. The authors noted that further research is needed to better understand the long-term effects of OCA on cholesterol and arterial atherosclerosis.\(^{[96]}\)

**GFT505**
GFT505 is a unique PPARα/δ agonist.\(^{[97]}\) PPARα activation, in combination with PPARβ/δ agonism, improves steatosis, inflammation, and fibrosis in preclinical models of NAFLD, identifying a new potential therapeutic area.\(^{[98]}\) Preclinical and clinical data had revealed improvement of insulin resistance,\(^{[98]}\) decrease in triglycerides and LDL levels, and significant improvement of the liver transaminases with this product.\(^{[98]}\) GFT505 had no induction of PPAR-driven genes in the skeletal muscles and hence will not produce any myalgia.\(^{[98]}\)
Anti-lysyl oxidase (mab)

Anti-lysyl oxidase is a promising monoclonal antibody still in phase II evaluation, which is believed to halt fibrosis and probably reverse some cirrhotic changes associated with NAFLD by inhibiting lysyl oxidase-like 2 (LOXL2), which promotes the cross-linking of type I collagen (a key component in the core regulatory pathway of fibrogenesis). This effect is expected to be exerted in a wide range of liver diseases leading to fibrosis and cirrhosis, regardless of the etiology.[56]

Metreleptin

The effect of leptin treatment is different when circulating leptin levels are low, normal, or high.[100] When the levels are low, leptin supplementation acquires adiponectin-like properties which render it appealing as a therapeutic target for NAFLD by decreasing hepatic and systemic IR and attenuating liver inflammation and fibrosis, as indicated from the hepatoprotective effect of the recombinant adiponectin against NASH.[100] Recombinant leptin (metreleptin) administered in patients with NAFLD and lipodystrophy decreased hepatic volume and steatosis, although had no effect on hepatic inflammation and fibrosis.[100] The discovery of adiponectin analogues, such as osmotin (a ligand for the yeast homologue of the adiponectin receptor), might provide a therapeutic alternative.[100]

Roflumilast and pioglitazone

Roflumilast and pioglitazone combination therapy is hypothesized to produce additive anti-inflammatory and hepatoprotective effects without overlapping toxicities. A randomized, double-blind, placebo-controlled, multicenter proof of mechanism phase II study is ongoing; it aims to evaluate the effect of roflumilast plus pioglitazone versus roflumilast and pioglitazone monotherapy versus placebo on liver enzymes and liver fat content based on MRI in patients with NASH after 4 months of treatment.[100]

Vitamin D

NAFLD patients have decreased serum 25-hydroxy vitamin D concentrations, suggesting that vitamin D may play a role in the development of NAFLD.[100] NAFLD and Vitamin D deficiency are often found associated, and while this is not unexpected, given their similar associations with obesity and sedentary lifestyle, a growing body of evidence points to a closely linked and potentially causative relationship between Vitamin D deficiency and NAFLD.[102] However it should be mentioned that vitamin D deficiency does exist with many other diseases and even in normal subjects as well hence a cause and effect relationship is extremely difficult to conclude. Vitamin D supplement in the treatment of NAFLD is not studied properly yet and the research seems to be in its earliest stages.

Testosterone replacement

Androgens may have a role in the pathogenesis of NAFLD particularly in hypogonadal men, those on testosterone replacement as well as the hypogonadism associated with obesity. Testosterone replacement in the hypogonadal men causes a significant reduction in weight, BMI, waist circumference, and circulating TNFα.[103] In obese men with obstructive sleep apnea, testosterone treatment reduced liver fat as measured by computed tomography (CT) without a reduction in BMI or weight.[104] Although altered liver enzymes are poorly predictive of steatohepatitis, testosterone administration has also been shown to decrease alanine transaminase and aspartate transaminase.[104]

Pradigastat

A randomized, multicenter, double-blind, placebo-controlled, parallel-group, 24-week pilot study[105] is ongoing to assess the efficacy, safety, and tolerability of LCQ908 (Pradigastat) in patients with nonalcoholic fatty liver disease (NCT01146522). The purpose of the core part of this study is to determine whether LCQ908 effectively lowers liver fat, as assessed by MRI and to assess its safety and tolerability profile in subjects with NAFLD. No study results are available yet.

Medicines in the pipeline

DUR-928 is an endogenous, small-molecule, new chemical entity that modulates the activity of several nuclear receptors, which play an important regulatory role in lipid homeostasis, inflammation, and cell survival and may have broad applicability in metabolic diseases such as NAFLD and NASH. It may also play an important role in protecting against acute kidney injury (AKI) and other types of acute organ injury. A systems biology study involving over 23,000 genes showed that DUR-928 modulates the activity of more than 240 genes, including ACC, FAS, HMGR, Cyp7A1, LXR, PPARγ, NFκB/κB, TNFα, IL-1α, IL-6, COX-2, PCSK9, and others. The biological activity of DUR-928 has been demonstrated in different animal models including NASH.[100]

GR-MD-02 is a carbohydrate-based galectin inhibitor that had shown in preclinical data from animal models of NASH with fibrosis to reduce hyaluronic acid in 33% of treated animals, as compared with the untreated ones. Phase I clinical study evaluated the safety, tolerability, and drug pharmacokinetics for single and multiple doses of GR-MD-02 when administered to human patients of NASH with advanced fibrosis. The medicine was safe and well tolerated and there were no serious adverse events reported. FibroTest®, was significantly reduced by GR-MD-02 treatment. The treatment effect was due to a statistically significant reduction of alpha-2 macroglobulin, one of the components of the score.[62]
Treatment of non alcoholic fatty liver disease, an overview.

Aramchol is a novel synthetic lipid molecule obtained by conjugating two natural components, cholic acid (a primary bile acid) and arachidic acid (a saturated fatty acid), through a stable amide bond. In a randomized, double-blind, placebo-controlled study of patients with biopsy-confirmed nonalcoholic fatty liver disease (NAFLD) or NASH, aramchol (500 mg daily for 3 months) was associated with lower liver fat content (a mean of 13% less), which is statistically significant compared with an increase in liver fat (a mean of 6% more) in patients who received placebo with improvement in endothelial function, levels of alanine aminotransferase and adiponectin. No serious or drug-related adverse events occurred in the treated patients.\(^{[65]}\)

RG-125 (AZD4076) an anti-microRNA targeting miR-103/107 function appeared to be unique insulin sensitizor. Inhibition of miR-103/107 leads to a sustained reduction in fasting glucose and fasting insulin levels and decrease in liver triglycerides and steatosis. Research is evaluating the effect of RG-125 on patients with NAFLD or NASH.\(^{[34]}\)

Cenicriviroc CVC is a dual inhibitor of the chemokine receptors CCR2 and CCR5 pathways, which play a key role in the cycle of inflammation and fibrosis. CVC has been shown in clinical trials to bind to both CCR2 and CCR5 targets. Food and Drug Administration has granted Fast Track designation to CVC for the treatment of NASH, in patients with liver fibrosis. A global randomized Phase IIb study CENTAUR (NCT02217475) of CVC versus placebo in patients with NASH and liver fibrosis is being carried out.\(^{[65]}\)

Phytomedication

Yo Jyo Hen Shi Ko

Yo jyo hen shi ko (YHK) is a Chinese herb that in a rat model, had prevented NASH, promoted weight loss, lowered serum aminotransferases, and reduced visceral fat.\(^{[106]}\) It appeared that it has an antioxidant, hypoglycemic, antifibrotic, and lipid-lowering properties\(^{[106,107]}\) and acts by promoting an increase in PPAR\(_\alpha\) and microsomal triglyceride transfer protein with a decrease in PPAR\(_\gamma\) mRNA contents. In a small clinical study of eight patients, after discontinuing YHK the ALT returned toward baseline at week 12. The mean decrease in ALT compared with that of baseline was significantly greater in the YHK group than in the placebo group at both week 4 and week 8 (\(P = 0.056, \) for both).\(^{[107]}\)

Folic acid

Folate deficiency is believed to affect NAFLD by causing a disturbance in hepatic methionine metabolism, which was shown to promote hepatic steatosis in the murine model.\(^{[99,108]}\) Low levels of vitamin B12 and folate were also observed in NASH and NAFLD patients but these low levels were not associated with either insulin resistance or the severity of liver disease.\(^{[109]}\) Neither vitamin B12 nor folate levels were significantly different within any histological category, including steatosis grade, fibrosis stage, lobular inflammation, portal inflammation and ballooning.\(^{[109]}\) A 6-month open-label pilot study of folic acid for the treatment of NAFLD did not show any improvement in serum aspartate and alanine aminotransferase levels (\(P = 0.5 \) and 0.6, respectively) in 10 patients with NASH.\(^{[108]}\)

Resveratrol

Resveratrol could protect the liver from NAFLD by reducing triglyceride accumulation and improving insulin resistance.\(^{[111]}\) Typical features of NAFLD, including histological changes, fibrosis, insulin resistance, oxidative stress, and inflammation were ameliorated by resveratrol treatment of knockout mice.\(^{[111]}\) This is achieved by activating AMP-activated protein kinase and reducing the activity of nuclear factor-kB (NF-kB) through the restoration of its inhibitor I\(\kappa B\).\(^{[111]}\) Therefore RSV has the therapeutic potential for preventing or treating NAFLD and IR-related metabolic disorders through regulating autophagic and I\(\kappa B\)–NF-kB pathways.\(^{[111]}\)

Anthocyanins

Anthocyanin, from different plant foods, have been shown to improve features of experimental NASH\(^{[112]}\) such as oxidative stress,\(^{[112,113]}\) dyslipidemia,\(^{[112]}\) liver steatosis,\(^{[112,113]}\) and inflammation\(^{[113]}\) in rodents. ACN-rich foods can be promising for the prevention of NAFLD and its complications.\(^{[113]}\) Purified anthocyanins may prevent the progression of liver damage related to NAFLD by three independent mechanisms: Inhibition of lipogenesis by reducing Srebplc, promotion of lipolysis by induction of PPAR\(_\alpha\) activity, and reduction of oxidative stress by induction of antioxidant enzymes. The effects of anthocyanins on lipid metabolism seem to be dependent on the activation of the AMPK pathway in hepatocytes\(^{[111]}\) by targeting protein kinase C, zeta (PKC\(_\zeta\)) thus they may contribute to the prevention and treatment of steatotic liver associated with obesity and T2DM.\(^{[112]}\) Additional studies are required to clarify the molecular mechanisms and to test the specific effect of single compounds and food extracts in vitro and in vivo.\(^{[113]}\)

Randomized controlled studies are warranted to test foods on histological damage or noninvasive biomarkers of liver damage progression in patients with NASH.\(^{[113]}\)

Quercetin

Treatment with quercetin may help to delay the progression of NAFLD, possibly by adjusting the balance of inflammatory cytokines. NAFLD rats have higher serum levels of IL-18 but lower levels of IL-10 than their healthy counterparts and these differential cytokine expressions may be related to liver inflammation and steatosis.\(^{[114]}\) It was found that the intracellular lipid content was significantly reduced following
quercetin therapy, which also strongly affected cellular lipid accumulation in a dose-dependent manner. Quercetin with allopurinol contributed to the reduction of liver inflammation and lipid accumulation under hyperglycemic conditions by inhibiting hepatic thioredoxin-interacting protein (TXNIP); this may have therapeutic implications for prevention of type 1 diabetes-associated NAFLD.

**Acarbose**

Acarbose is an alpha-glucosidase inhibitor, which can lead to an increase in the total adiponectin levels. Together with pioglitazone, they decreased HbA1c values by 0.49% and 0.65%, respectively, in 17 patients with T2DM and 16 for pioglitazone during three months treatment. Treatment with acarbose and pioglitazone increased the serum levels of total adiponectin by 2.1-fold and its high molecular weight isoform by 3.6-fold, which makes the combination a useful agent for the treatment of NAFLD. Both ezetimibe and acarbose improved metabolic and biochemical abnormalities in patients with NASH; however, these effects were more prominent with ezetimibe. The combination therapy with ezetimibe and acarbose for 24 weeks also improved the histopathological findings in a mouse model of NAFLD.

**Coffee**

Coffee consumption is a popular lifestyle choice worldwide; at least 50% of US adults consume coffee on a daily basis. Beneficial effects of coffee have been observed in multiple chronic medical conditions including T2DM, Parkinson disease, prostate cancer, hepatitis C virus (HCV), HCC, and more recently, NAFLD. Moreover, a large population-based study found that increasing coffee intake is associated with a modest decrease in all-cause mortality. Coffee has inverse relationships with both T2DM and hepatic fibrosis in patients with NAFLD. Relationships were explored between coffee intake and insulin resistance (IR) with respect to NAFLD histological severity. In one of large studies, among 782 participants (24% of them having diabetes), NASH was present in 79%. Coffee intake was shown to be inversely associated with advanced fibrosis among NAFLD patients with lower HOMA-IR.

**HEPATOPROTECTIVE AGENTS**

Historically speaking, several compounds have been claimed to have a theoretical protective effect on the liver cells, which in some patients could be clinically relevant and had been applied in practice either on empiric, local experience, or traditional management basis. Some of these products are available as nutritional supplements and may have a convincing rationale, whereas some others such as “essential phospholipids (EPL) may have evidence furnished on research basis. These medicines included N-Acetyl Cysteine, Choline Bitartrate, Artichoke Extract, Dandelion Root, taraxacin and inulin, Turmeric (curcumin), Milk Thistle Extract (Silymarin), Essential phospholipids, UCDA, vitamin E, S-Adenosyl Methionine, Ganoderma spores, traditional Chinese medicine, including Gansu and some herbal compounds.

Phosphatidylcholine (PC), a main component of EPL, is one of the most important support nutrients for the liver and is considered as a universal building block for cell membranes, which regulate the vast majority of the activities that make up life. PC helps recovery and maintenance of the consistency of the hepatocytes; it activates the phospholipid-depending enzymes and improves lipid metabolism by accelerating synthesis of lipoproteins in the liver. Studies have demonstrated that EPL will activate synthesis of RNA and as a result lead to the normalization of protein metabolism. It exerts a good effect on glycogenesis and improves the detoxification function of the liver. All of these effects may lead to a reduction of the fatty infiltration of the hepatocytes. Many clinical trials indicated that EPL protected the liver against damage in patients diagnosed with NAFLD with an improvement in clinical symptoms, liver function, and liver structure evaluated by ultrasonography imaging.

In an open-label observational study, we looked into the efficacy of EPL as an adjunctive agent in treating 324 patients of primary NAFLD or NAFLD associated with comorbid clinical conditions such as T2DM and hyperlipidemia. It was concluded from the study that there was a significant improvement for all symptoms, general and gastrointestinal, and a significant reduction of the elevated transaminases ($P < 0.001$ baseline vs endpoint) associated with NAFLD disease. The study had also demonstrated a mild but noteworthy improvement in fatty infiltration ($P = 0.7$) as concluded from changes of liver ultrasonography as well as a positive impact on liver stiffness measurement associating fibrosis of the liver as indicated from liver elastography. Extended treatment seemed to further benefit patients leading to stabilization of liver function and maintaining recovery.

Silymarin and silibinin, the active products of milk thistle have shown in several pharmacological studies hepatoprotective, antioxidant, anti-inflammatory, and antifibrotic properties; in addition, they stimulate protein biosynthesis and liver regeneration and have immunomodulatory activity. They also improve insulin resistance, reduce lipidperoxidation, and restore GSH levels, which makes it another suitable herb for use against liver steatosis.

**CONCLUSION**

A decade of clinical trials involving a diversity of pharmaceutical agents targeting the pathological concepts
Treatment of non-alcoholic fatty liver disease, an overview.

of NAFLD did not reveal a single intervention that has convincingly improved all important outcomes for all NASH patients. Therefore, in 2015, there was no single medication that can be recommended as a target-specific agent for routine clinical use for all patients of NAFLD. It remains that the best available treatment should be instructing patients to follow a reasonable dietary plan and a tailored exercise program. Together with this, patients should be treated for any associated comorbid disease in accordance with a specific medicine from the list of medications discussed in this review. Liver protection should be an important part of the management plan complementing lifestyle modification and other medications that the patient may be taking. A liver-protective agent such as EPL or sylimarin may be added to the management plan. EPL had emerged as an important additive nutritional support that has a favorable effect on most NAFLD patients. There is no enough convincing evidence to support the use of medicines that were long used on empiric basis such as vitamin E, UDCA, and SAMe for treatment of NAFLD, hence they are not recommended in most guidelines as standard treatment of NAFLD. The impact of the treatment adopted for fibrosis caused by NASH is not convincing so far, although pentoxifylline may have some effect. The anti-lysyl oxidase monoclonal antibodies, proposed to reduce fibrosis and reverse cirrhosis may be the choice in this respect. The new medications in the pipeline being currently evaluated such as OCA, GFT505, metreleptin, and pradigastat and the probiotics should provide a hope for the future as target-specific agents when they furnish good clinical evidence after phase III results. Testosterone replacement may be indicated for hypogonadal men. For the very obese patients, weight reduction surgery may improve NASH but data of long-term outcome and enough RCT are lacking.

Financial support and sponsorship
Nil.

Conflicts of interest
There are no conflicts of interest.

REFERENCES

1. Chitturi S, Wong VW, Farrell G. Nonalcoholic fatty liver in Asia: Firmly entrenched and rapidly gaining ground. J Gastroenterol Hepatol 2011;26(Suppl 1):163-72.
2. Masarone M, Federico A, Abenavoli L, Loguercio C, Persico M. Non-alcoholic fatty liver: Epidemiology and natural history. Rev Recent Clin Trials 2014;9:126-33.
3. Söderberg C, Stål P, Asklings J, Glaumann H, Lindberg G, Marmur J, et al. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology 2010;51:595-602.
4. Yatsuji S, Hashimoto E, Tobari M, Tanai M, Tokushige K, Shiratori K. Clinical features and outcomes of cirrhosis due to non-alcoholic steatohepatitis compared with cirrhosis caused by chronic hepatitis C. J Gastroenterol Hepatol 2009;24:248-54.
5. Nascimbeni F, Pais R, Bellentani S, Day CP, Ratziu V, Loria P, et al. From NAFLD in clinical practice to answers from guidelines. J Hepatol 2013;59:859-71.
6. Musso G, Cassader M, Rosina F, Gambino R. Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis of randomised trials. Diabetologia 2012;55:885-904.
7. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al.; American Association for the Study of Liver Diseases; American College of Gastroenterology; American Gastroenterological Association. The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Am J Gastroenterol 2012;107:811-26.
8. Babio N, Toledo E, Estruch R, Ros E, Martinez-González MA, Castañer O, et al. Mediterranean diets and metabolic syndrome status in the PREDIMED randomized trial. CMAJ 2014;186:E49-57.
9. Gasteiger C, Larsen TM, Ver Cyrusse F, Astrup A. Effect of a dietary-induced weight loss on liver enzymes in obese subjects. Am J Clin Nutr 2008;87:1141-7.
10. Lazo M, Solga SF, Horska A, Bonekamp S, Diehl AM, Brancati FL, et al.; Fatty Liver Subgroup of the Look AHEAD Research Group. Effect of a 12-month intensive lifestyle intervention on hepatic steatosis in adults with type 2 diabetes. Diabetes Care 2010;33:2156-63.
11. Albu JB, Heilbronn LK, Kelley DE, Smith SR, Azuma K, Berk ES, et al.; Look AHEAD Adipose Research Group. Metabolic changes following a 1-year diet and exercise intervention in patients with type 2 diabetes. Diabetes 2010;59:627-33.
12. Zelber-Sagi S, Kessler A, Brazovsky E, Webb M, Lurie Y, Santo M, et al. A double-blind randomized placebo-controlled trial of orlistat for the treatment of non-alcoholic fatty liver disease. Clin Gastroenterol Hepatol 2006;4:639-44.
13. Harrison SA, Fecht W, Brunt EM, Neuschwander-Tetri BA. Orlistat for overweight subjects with nonalcoholic steatohepatitis: A randomized, prospective trial. Hepatology 2009;49:80-6.
14. European Medicine Agency. Xenical 120 mg Summary of Product Characteristics. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000154/WCS00058428.pdf. [Last accessed on 2015 Apr 19].
15. Hafez S, Ahmed MH. Bariatric surgery as potential treatment for non-alcoholic fatty liver disease: A future treatment by choice or by chance? J Obes 2013;2013:839275.
16. Chavez-Tapia NC, Tellez-Avila FI, Barrientos-Gutierrez T, Mendez-Sanchez N, Lizardi-Cervera J, Uribe M. Bariatric surgery for non-alcoholic steatohepatitis in obese patients. Cochrane Database Syst Rev 2010;CD007340.
17. Mummadri RR, Kasturi KS, Chennareddyga S, Sood GK. Effect of bariatric surgery on nonalcoholic fatty liver disease: Systematic review and meta-analysis. Clin Gastroenterol Hepatol 2008;6:1396-402.
18. D’Albuquerque LA, Gonzalez AM, Wahle RC, de Oliveira Souza E, Mancero JM, de Oliveira e Silva A. Liver transplantation for subacute hepatocellular failure due to massive steatohepatitis after bariatric surgery. Liver Transpl 2008;14:881-5.
19. Sasaki A, Nitta H, Otusuka K, Umemura A, Baba S, Obuchi T, et al. Bariatric surgery and non-alcoholic fatty liver disease: Current and potential future treatments. Front Endocrinol (Lausanne) 2014;5:164.
20. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Zoili M, Melchionda N. Metformin in non-alcoholic steatohepatitis. Lancet 2001;358:893-4.
21. Uygun A, Kadayifci A, Isik AT, Ozgurtas T, Deveci S, Tuzun A, et al. Metformin in the treatment of patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2004;19:537-44.

22. Bugianesi E, Gentilcore E, Manini R, Natale S, Vanni E, Villanova N, et al. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am J Gastroenterol 2005;100:1082-90.

23. Lavine JE, Schwimmer JB, Van Natta ML, Mollerston JP, Murray KE, Rosenthal P, et al. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: The TONIC randomized controlled trial. JAMA 2011;305:1659-68.

24. Mazza A, Fruci B, Garinis GA, Giuliano S, Malaguarnera R, Belfiore A. The role of metformin in the management of NAFLD. Exp Diabetes Res 2012;2012:716404.

25. Shadid S, Jensen MD. Effect of pioglitazone on biochemical indices of non-alcoholic fatty liver disease in upper body obesity. Clin Gastroenterol Hepatol 2003;1:384-7.

26. Aithal GP, Thomas JA, Kaye PV, Lawson A, Ryder SD, Spendlove I, et al. Randomized, placebo-controlled trial of pioglitazone in nonalcoholic subjects with nonalcoholic steatohepatitis. Gastroenterology 2008;135:1176-84.

27. Sanyal AJ, Chalasani N, Kowdle KV, McCullough A, Diehl AM, Bass NM, et al. NASH CRN. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010;362:1675-85.

28. Mahady SE, Webster AC, Walker S, Sanyal A, George J. The role of thiazolidinediones in non-alcoholic steatohepatitis - a systematic review and meta-analysis. J Hepatol 2011;55:1383-90.

29. Foster T, Budoff MJ, Saab S, Ahmed N, Gordon C, Guerci AD. Atorvastatin for the treatment of NASH. Hepatology 2011;54:1610-9.

30. Gómez-Dominguez E, Gisbert JP, Moreno-Monteagudo JA, García-Buey L, Moreno-Otero R. A pilot study of atorvastatin treatment in dyslipidem, non-alcoholic fatty liver patients. Aliment Pharmacol Ther 2006;23:1643-7.

31. Horlander J, Kwo P. Atorvastatin for the treatment of NASH. Hepatology 1997;26:544A.

32. Kiyici J, Gulten M, Gurel S, Nak SG, Dolar E, Savci G, et al. Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis. Can J Gastroenterol 2003;17:713-8.

33. Park H, Shima T, Yamaguchi K, Minami M, Yasui K, et al. Efficacy of long-term ezetimibe therapy in patients with nonalcoholic fatty liver disease. J Gastroenterol 2011;46:101-7.

34. Loomber R, Sirlin CB, Ang B, Bennett J, Jain R, Salotti J, et al; San Diego Integrated NAFLD Research Consortium (SINC). Ezetimibe for the treatment of nonalcoholic steatohepatitis: Assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial) Hepatology 2015;61:239-50.

35. Lavine JE. Vitamin E treatment of non-alcoholic steatohepatitis in children: A pilot study. J Pediatr 2000;136:734-8.

36. Hasegawa T, Yoneda M, Nakamura K, Makino I, Terano A. Plasma transforming growth factor-beta1 level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis: A pilot study. Aliment Pharmacol Ther 2001;15:1667-72.

37. Harrison SA, Torgerson S, Hayashi P, Ward J, Schenker S, Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2003;98:2348-50.

38. Cacciapuoti F, Scognamiglio A, Palumbo R, Forte R, Cacciapuoti F. Silymarin in non alcoholic fatty liver disease. World J Hepatol 2013;5:109-13.

39. Solhi H, Ghaehremani R, Kazemifar AM, Hoseini Yazdi Z. Silymarin in treatment of non-alcoholic steatohepatitis: A randomized clinical trial. Caspian J Intern Med 2014;5:9-12.

40. Hashemi SJ, Hajiani E, Sardabi EH. A placebo-controlled trial of silymarin in patients with nonalcoholic fatty liver disease. Hepat Mon 2009;9:265-70.

41. Li W, Zheng L, Sheng C, Cheng X, Qing L, Qu S. Systematic review on the treatment of pentoxifylline in patients with non-alcoholic fatty liver disease. Lipids Health Dis 2011;10:49.

42. Zein CO, Yerian LM, Mogate P, Lopez R, Kirwan JP, Feldstein AE, et al. Pentoxifylline improves nonalcoholic steatohepatitis: A randomized placebo-controlled trial. Hepatology 2011;54:1610-9.

43. Georgescu EF. Angiotensin receptor blockers in the treatment of NASH/NAFLD: Could they be a first-class option? Adv Ther 2008;25:1141-74.

44. Abu Dayyeh BK, Yang M, Dienstag JL, Chung RT. The effects of angiotensin blocking agents on the progression of liver fibrosis in the HALT-C trial cohort. Dig Dis Sci 2011;56:564-8.

45. Lugo-Baruqui A, Muñoz-Valle J, Arévalo-Gallegos S, Armendáriz-Borunda J. Role of angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology 2004;40:1222-5.

46. Gonciarz Z, Besier P, Lelek E, Gundermann KJ, Johannes KJ. Randomized placebo-controlled double-blind trial on “essential” phospholipids in the treatment of fatty liver associated with diabetes. Med Chin Dig 1998;17:61-5.

47. Arvind N, Savaikar P, Rajkumar JS. Therapy for NAFLD: A comparative study of essential phospholipids vs. ursodeoxycholic acid. Ind J Clin Pract 2006;16:21-4.

48. Dajani AI, Abu Hamour AM, Zakaria MA, Al Jaberi MR, Nounou MA, Semrin AI. Essential phospholipids as a supportive adjunct in the management of patients with NAFLD. Arab J Gastroenterol 2015;[Epub ahead of print].

49. Kajikawa S, Imada K, Takeuchi T, Shimizu Y, Kawashima A, Harada T, et al. Eicosapentaenoic acid attenuates progression of hepatic fibrosis with inhibition of reactive oxygen species production in rats fed methionine- and choline-deficient diet. Dig Dis Sci 2011;56:1065-74.

50. Tanaka N, Sano K, Horiuchi A, Tanaka E, Kiyosawa K, Aoyama T. Highly purified eicosapentaenoic acid treatment improves nonalcoholic steatohepatitis. J Clin Gastroenterol 2008;42:413-8.

51. Sanyal AJ, Abdelmalek ME, Suzuki A, Cummings OW, Chojkier M; EPE-A Study Group. No significant effects of ethyl-eicosapentaenoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 trial. Gastroenterology 2014;147:377-84.e1.

52. Ma YY, Li L, Yu CH, Shen Z, Chen LH, Li YM. Effects of probiotics on nonalcoholic fatty liver disease: A meta-analysis. World J Gastroenterol 2013;19:6911-8.

53. Vajo P, Mandato C, Licenziati MR, Frances A, Vitale DF, Lenta S, et al. Effects of Lactobacillus rhamnosus strain GG in pediatric obesity-related liver disease. J Pediatr Gastroenterol Nutr 2011;52:740-3.

54. Abenavoli L, Scarpellini E, Rouabhia S, Balsano C, Luzza F. Probiotics in obstructive liver diseases: Which and when. Ann Hepatol 2011;106:71-7.

55. Ikenaga N, Yoshida S, Liu SB, Chung J, Sverdlov D, Marshall D, et al. The effects of probiotics on biochemical indices of non-alcoholic fatty liver disease. J Hepatol 2011;54:1756-66.

56. Yokohama S, Yoneda M, Haneda M, Okamoto S, Okada M, Aso K, et al. Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology 2004;40:1222-5.

57. Mudaliar S, Henry RR, Sanyal AJ, Morrow L, Marschall HU, Kipnes M, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis: NASH CRN. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010;362:1675-85.
in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology 2013;145:574-82.e1.

58. Cariou B, Staels B. GFT505 for the treatment of nonalcoholic steatohepatitis and type 2 diabetes. Expert Opin Investig Drugs 2014;23:1441-8.

59. Staels B, Rubenstriuk A, Noel B, Rigou G, Delataille P, Millatt LJ, et al. Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Hepatology 2013;58:1941-52.

60. DJUR-928. Available from: http://www.durect.com/wt/durect/page_name_DJUR-928. [Last accessed on 2015 May 25].

61. Traber PG, Chou H, Zomer E, Hong F, Klyosov A, Fiel MI, et al. Regression of fibrosis and reversal of cirrhosis in rats by galectin inhibitors in thioacetamide-induced liver disease. PLoS One 2013;8:e73361.

62. Harrison S. Galectin Therapeutics’: Phase 1 Data Advances GR-MD-02 in to Phase 2 Clinical Development. Presented at AASLD Annual Meeting 2014. Available from: www.galactintherapeutics.com/releasedetail.cfm?releaseID=897897. [Last accessed on 2015 May 25].

63. Safadi R, Konikoff FM, Mahamid M, Zelber-Sagi S, Halpern M, Gilat T, et al. The fatty acid-bile acid conjugate arachmol reduces liver fat content in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2014;12:2085-91.e1.

64. Regulus Reports First Quarter 2015 Financial Results and Recent Highlights. Available from: http://www.researchviews.com/healthcare/pharma/infectiousdisease/NewsReport.aspx?Type=1&sector=InfectiousDisease&ArticleID=4571857. [Last accessed on 2015 May 25].

65. Sanyal AJ, Friedman SL, McCullough AJ, Dimick-Santos L: American Association for the Study of Liver Diseases; United States Food and Drug Administration. Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: Findings and recommendations from an American Association for the Study of Liver Diseases-U.S. Food and Drug Administration Joint Workshop. Hepatology 2015;61:1392-405.

66. Stein LL, Dong MH, Loomba R. Insulin sensitizers in nonalcoholic fatty liver disease and steatohepatitis: Current status. Adv Ther 2009;26:893-907.

67. Nair S, Dielbl AM, Wiseman M, Farr GH Jr, Perrillo RP. Metformin in the treatment of non-alcoholic steatohepatitis: A pilot open label trial. Aliment Pharmacol Ther 2004;20:23-8.

68. Mahady S. Therapies for nonalcoholic steatohepatitis. Gastroenterol Hepatol (N Y) 2013;9:40-2.

69. Xiao WH, Wang YR, Hou WF, Xie C, Wang HN, Hong TP, et al. The effects of pioglitazone on biochemical markers of bone turnover in patients with type 2 diabetes. Int J Endocrinol 2013;200734.

70. Fernández-Miranda C, Pérez-Carreras M, Colina F, López-Alonso G, Vargas C, Solís-Herruzo JA. A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease. Dig Liver Dis 2008;40:200-5.

71. Nseir W, Mahamid M. Statins in nonalcoholic fatty liver disease and steatohepatitis: Updated review. Curr Atheroscler Rep 2013;15:305.

72. Neto-Ferreira R, Rocha VN, Souza-Mello V, Mandarim-de-Lacerda CA, de Carvalho JF. Pleiotropic effects of rosuvastatin on the glucose metabolism and the subcutaneous and visceral adipose tissue behavior in C57Bl/6 mice. Diabetol Metab Syndr 2013;5:32.

73. Argo CK, Loria P, Caldwell SH, Lonardo A. Statins in liver disease: A molehill, an iceberg, or neither? Hepatology 2008;48:662-9.

74. Riche DM, Fleming JW, Malinowski SS, Black CA, Miller KH, Wofford MR. Resistant nonalcoholic fatty liver disease amelioration with rosuvastatin and pioglitazone combination therapy in a patient with metabolic syndrome. Ann Pharmacother 2014;48:137-41.

75. Nakou ES, Filippatos TD, Agouridis AP, Kostara C, Bairaktari ET, Eliaf MS. The effects of ezetimibe and/or orlistat on triglyceride-rich lipoprotein metabolism in obese hypercholesterolemic patients. Lipids 2010;45:445-50.

76. Filippatos TD, Eliaf MS. Role of ezetimibe in non-alcoholic fatty liver disease. World J Hepatol 2011;30:265-7.

77. Shu X, Zhang L, Ji G. Vitamin E therapy in non-alcoholic fatty liver disease. Int J Clin Med 2014;5:87-92.

78. Pascana T, Sanyal AJ. Vitamin E and nonalcoholic fatty liver disease. Curr Opin Clin Nutr Metab Care 2012;15:641-8.

79. Mitchel EB, Lavine JE. Review article: The management of paediatric nonalcoholic fatty liver disease. Aliment Pharmacol Ther 2014;40:1155-70.

80. Adams LA, Angulo P. Treatment of non-alcoholic fatty liver disease. Postgrad Med J 2006;82:015-22.

81. Mouzaki, Allard J. Non-alcoholic steatohepatitis: The therapeutic challenge of a global epidemic. Ann Gastroenterol 2012;25:207-17.

82. Kot BA. Molecular mechanisms of ursodeoxycholic acid toxicity and side effects: Ursodeoxycholic Acid freezes regeneration & induces hibernation mode. Int J Mol Sci 2012;13:8882-914.

83. Blaslov K, Bulum T, Zibar K, Dunjjak L. Incretin based therapies: A novel treatment approach for non-alcoholic fatty liver disease. World J Gastroenterol 2014;20:7356-65.

84. Liu J, Wang G, Jia Y, Xu Y. GLP-1 receptor agonists: Effects on the progression of non-alcoholic fatty liver disease. Diabetes Metab Res Rev 2015;31:329-35.

85. Balaban YH, Korkusuz P, Simsek H, Gokcan H, Gedikoglu G, Pinar A, et al. Dipeptidyl peptidase IV (DPP IV) in NASH patients. Ann Hepatol 2007;6:242-50.

86. Zeng T, Zhang CL, Zhao XL, Xie XQ. Pentoxifylline for the treatment of nonalcoholic fatty liver disease: A meta-analysis of randomized double-blind, placebo-controlled studies. Eur J Gastroenterol Hepatol 2014;26:646-53.

87. Du J, Ma YY, Yu CH, Li YM. Effects of pentoxifylline on nonalcoholic fatty liver disease: A meta-analysis. World J Gastroenterol 2014;20:569-77.

88. Paschos P, Tziomalos K. Nonalcoholic fatty liver disease and the renin-angiotensin system: Implications for treatment. World J Hepatol 2012;4:327-31.

89. Anstee YM, Day CP. S-adenosylmethionine (SAMe) therapy in liver disease: A review of current evidence and clinical utility. J Hepatol 2012;57:1097-109.

90. Lam B, Younossi ZM. Treatment options for nonalcoholic fatty liver disease. Therap Adv Gastroenterol 2010;3:121-37.

91. Study to Investigate the Effects of Different Doses of S-adenosyl-L-methionine (SAMe) in Subjects With Nonalcoholic Fatty Liver Disease and Non-treated Matched Healthy Volunteers as Control Group (EXPO). Available from: https://clinicaltrials.gov/ct2/show/NCT01754714?term=S-Adenosyl+Methionine+and+NAFLDandrank=1. [Last accessed on 2015 May 25].

92. Wong VW, Won GL, Chim AM, Chu WC, Yeung DK, Li KC. S-adenosyl-L-methionine (SAMe) in Subjects With Nonalcoholic Fatty Liver Disease. Therap Adv Gastroenterol 2010;3:121-37.

93. Mencarelli A, Ciprani S, Renga B, Bruno A, D’Amore C, Distretti E, et al. VSL#3 resets insulin signaling and protects against NASH and atherosclerosis in a model of genetic dyslipidemia and intestinal inflammation. PLoS One 2012;7:e45425.

94. Kelishadi R, Farajian S, Mirlohi M. Probiotics as a novel treatment for non-alcoholic fatty liver disease; a systematic review on the current evidences. Hepat Mon 2013;13:e7233.

95. Paolella G, Mandato C, Pierri L, Poeta M, Di Stasi M, Vajro P. Gut-liver axis and probiotics: Their role in non-alcoholic fatty liver disease. World J Gastroenterol 2014;20:15518-31.
Dajani and AbuHammour

96. Ali AH, Carey EJ, Lindor KD. Recent advances in the development of farnesoid X receptor agonists. Ann Transl Med 2015;3:5.

97. Cariao B, Zair Y, Staels B, Bruckert E. Effects of the new dual PPAR α/δ agonist GFT505 on lipid and glucose homeostasis in abdominally obese patients with combined dyslipidemia or impaired glucose metabolism. Diabetes Care 2011;34:2008-14.

98. Cariao B, Hanf R, Lambert-Porcheron S, Zair Y, Sauvinin V, Noël B, et al. Dual peroxisome proliferator-activated receptor α/δ agonist GFT505 improves hepatic and peripheral Insulin sensitivity in abdominally obese subjects. Diabetes Care 2013;36:2923-30.

99. Polyzos SA, Kountouras J, Patsiaoura K, Katsiki E, Zaefiriadou E, Zavos C, et al. Serum vitamin B12 and folate levels in patients with non-alcoholic fatty liver disease. Int J Food Sci Nutr 2012;63:659-66.

100. Pearlman M, Loomba R. State of the art: Treatment of nonalcoholic steatohepatitis. Liver Int 2007;27:220-6.

101. Shang J, Chen LL, Xiao FX, Zhang Y, Peng H, Li K, et al. Resveratrol and allopurinol reduce liver thioredoxin-interacting protein to alleviate inflammation and lipid accumulation in diabetic rats. Br J Pharmacol 2013;169:1352-7.

102. Kwok RM, Torres DM, Harrison SA. Vitamin D and nonalcoholic fatty liver disease. Aliment Pharmacol Ther 2013;38:246-54.

103. Kwon YK, Kim DH, Hur JY, Park JH, Kwon HJ, et al. Meta-analysis: Vitamin D and non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2013;38:1166-74.

104. Kalinchenko SY, Tishova YA, Mkhaklaya GJ, Gooren LJ, Giltn Ev, Saad E. Effects of testosterone supplementation on markers of the metabolic syndrome and inflammation in hypogonadal men with the metabolic syndrome: The double-blind placebo-controlled Moscow study. Clin Endocrinol (Oxf) 2010;73:602-12.

105. Hoyos CM, Yee BJ, Phillips CJ, Machan EA, Grunstein RR, Liu PY. Body compositional and cardiometabolic effects of testosterone therapy in obese men with severe obstructive sleep apnoea: A randomised placebo-controlled trial. Eur J Endocrinol 2012;167:531-41.

106. Stefano JT, de Oliveira CP, Corrêa-Giannella ML, de Lima VM, de Sá SV, de Oliveira EP, et al. Nonalcoholic steatohepatitis (NASH) in ob/ob mice treated with yo jyo hen shi ko (YHK): Effects on peroxisome proliferator-activated receptors (PPARs) and microsomal triglyceride transfer protein (MTP). Dig Dis Sci 2007;52:3448-54.

107. Chande N, Laidlaw M, Adams P, Marotta P, Yo Jyo Hen Shi Ko (YHK) improves transaminases in nonalcoholic steatohepatitis (NASH): A randomized pilot study. Dig Dis Sci 2006;51:1183-9.

108. Charatcharoenwitthaya P, Levy C, Angulo P, Keach J, Jorgensen R, Lindor KD. Open-label pilot study of folate in patients with nonalcoholic steatohepatitis. Liver Int 2007;27:220-6.

109. Setola E, Monti LD, Gulluccio E, Pallosi A, Fragasso G, Paroni R, et al. Insulin resistance and endothelial function are improved after folate and vitamin B12 therapy in patients with metabolic syndrome: Relationship between homocysteine levels and hyperinsulinemia. Eur J Endocrinol 2004;151:483-9.

110. Shang J, Chen LL, Xiao FX, Sun H, Ding HC, Xiao H. Resveratrol improves non-alcoholic fatty liver disease by activating AMP-activated protein kinase. Acta Pharmacol Sin 2008;29:698-706.

111. Li L, Hai J, Li Z, Zhang Y, Peng H, Li K, et al. Resveratrol modulates autophagy and NF-kB activity in a murine model for treating non-alcoholic fatty liver disease. Food Chem Toxicol 2014;63:166-73.

112. Guo H, Li D, Ling W, Feng X, Xia M. Antioxidant inhibits high glucose-induced hepatic mtGPAT1 activation and prevents fatty acid synthesis through PKCε, J Lipid Res 2011;52:908-22.

113. Valenti L, Riso P, Mazzucchelli A, Porrini M, Fargion S, Agostoni C. Dietary anthocyanins as nutritional therapy for nonalcoholic fatty liver disease. Oxid Med Cell Longev 2013;2013:145421.

114. Marcolin E, San-Miguel B, Vallejo D, Tieppo J, Marroni N, Gonzalez-Gallego J, et al. Quercetin treatment ameliorates inflammation and fibrosis in mice with nonalcoholic steatohepatitis. J Nutr 2012;142:1821-8.

115. Li X, Wang R, Zhou N, Wang X, Liu Q, Bai Y, et al. Quercetin improves insulin resistance and hepatic lipid accumulation in vitro in a NAFLD cell model. Biomed Rep 2013;1:71-6.

116. Wang W, Wang C, Ding XQ, Pan Y, Gu TT, Wang MX, et al. Quercetin and allopurinol reduce liver thioredoxin-interacting protein to alleviate inflammation and lipid accumulation in diabetic rats. Br J Pharmacol 2013;169:1352-7.

117. Ochihi H, Ooka H, Shida C, Ishikawa T, Inoue D, Okazaki R. Acarbose treatment increases serum total adiponectin levels in patients with type 2 diabetes. Endocr J 2008;55:549-56.

118. Hajiaghamohammadi AA, Mirolaeae A, Sani A, Alborzi F, Ziaee A. A comparison of ezetimibe and acarbose in decreasing liver transaminase in nonalcoholic fatty liver disease: A randomized clinical trial. Govaresh 2013;18:186-90.

119. Nozaki Y, Fujita K, Yoneda M, Wada K, Shinohara Y, Takahashi H, et al. Long-term combination therapy of ezetimibe and acarbose for non-alcoholic fatty liver disease. J Hepatol 2009;51:548-56.

120. Bambha K, Wilson LA, Unalp A, Loomba R, Neuschwander-Tetri BA, Brunt EM, et al. Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN). Coffee consumption in NAFLD patients with lower insulin resistance is associated with lower risk of severe fibrosis. Liver Int 2014;34:1250-8.

121. Saab S, Mallam D, Cox GA 2nd, Tong MJ. Impact of coffee on liver diseases: A systematic review. Liver Int 2014;34:495-504.

122. Buang Y, Wang YM, Cha JY, Nagao K, Yanagita T. Dietary phosphatidylcholine and vitamin E in patients with nonalcoholic fatty liver disease type-2 diabetes and non-alcoholic fatty liver disease. Clinical Focus 2012;52:1658-65.

123. Gundermann KJ, Kuenker A, Kuntz E, Drozdzik M. Activity of essential phospholipids (EPL) from soybean in liver diseases. Pharmacol Rep, 2013;65. p. 643-59.

124. Yen D, Kong L. Observation for curative effect of essentiE in treatment of fatty liver caused by diabetes mellitus. Med J Q Ilu 2000;15:277-8.

125. Du Q, Treatment of 52 cases with hepatic dysfunctional fatty liver with essential phosphatidylcholine and metformin in the treatment of fatty liver disease: A systematic review. Liver Int 2014;34:21-4.

126. Padma L, Mukaddam Q, Trailokya A. An Observational Study of the clinical study. J Hepatol 2013;58(Suppl 1):S549. [Last accessed on 2013 Jun 1].

127. Stefano JT, de Oliveira CP, Corrêa-Giannella ML, de Lima VM, de Sá SV, de Oliveira EP, et al. Nonalcoholic steatohepatitis (NASH) in ob/ob mice treated with yo jyo hen shi ko (YHK): Effects on peroxisome proliferator-activated receptors (PPARs) and microsomal triglyceride transfer protein (MTP). Dig Dis Sci 2007;52:3448-54.

128. Chande N, Laidlaw M, Adams P, Marotta P. Yo Jyo Hen Shi Ko (YHK) improves transaminases in nonalcoholic steatohepatitis (NASH): A randomized pilot study. Dig Dis Sci 2006;51:1183-9.

129. Charatcharoenwitthaya P, Levy C, Angulo P, Keach J, Jorgensen R, Lindor KD. Open-label pilot study of folate in patients with nonalcoholic steatohepatitis. Liver Int 2007;27:220-6.

130. Setola E, Monti LD, Gulluccio E, Pallosi A, Fragasso G, Paroni R, et al. Insulin resistance and endothelial function are improved after folate and vitamin B12 therapy in patients with metabolic syndrome: Relationship between homocysteine levels and hyperinsulinemia. Eur J Endocrinol 2004;151:483-9.

131. Shang J, Chen LL, Xiao FX, Sun H, Ding HC, Xiao H. Resveratrol improves non-alcoholic fatty liver disease by activating AMP-activated protein kinase. Acta Pharmacol Sin 2008;29:698-706.

132. Li L, Hai J, Li Z, Zhang Y, Peng H, Li K, et al. Resveratrol modulates autophagy and NF-kB activity in a murine model for treating non-alcoholic fatty liver disease. Food Chem Toxicol 2014;63:166-73.

133. Guo H, Li D, Ling W, Feng X, Xia M. Antioxidant inhibits high glucose-induced hepatic mtGPAT1 activation and prevents fatty acid synthesis through PKCε, J Lipid Res 2011;52:908-22.
132. Zeng JT, Chen J. Clinical observation on the results in treatment of NAFLD with polyene phosphatidylcholine combined with Xuezhikang capsules. China Trop Med 2008;8:778-9.

133. Dajani AI, Abu Hammour AM, Zakaria MA, Al Jaberi M, Nounou MA. Essential phospholipids as a supportive adjunct to the management of patients with primary NAFLD and NAFLD associated with type 2 diabetes mellitus or hyperlipidaemia. Hepatol Int 2013;7(Suppl 1):S1-754.

134. Abenavoli L, Aviello G, Capasso R, Milic N, Capasso F. Milk thistle for treatment of nonalcoholic fatty liver disease. Hepat Mon 2015;11:173-7.

135. Abenavoli L, Capasso R, Milic N, Capasso F. Milk thistle in liver diseases: Past, present, future. Phytother Res 2010;24:1423-32.